Literature DB >> 32354900

Significant Association of Interleukin-16 Genetic Variations to Taiwanese Lung Cancer.

Meng-Feng Wu1,2,3, Yun-Chi Wang1,2, Te-Chun Shen1,2, Wen-Shin Chang1,2, Hsin-Ting Li2, Cheng-Hsi Liao1,2, Chi-Li Gong2, Zhi-Hong Wang4, Chia-Wen Tsai5,2, Te-Chun Hsia6,7,8, DA-Tian Bau5,2,9.   

Abstract

BACKGROUND/AIM: Interleukin-16 has been reported to exhibit tumoricidal effects, however, the contribution of IL-16 genotypes to lung cancer is still largely unrevealed. This study aimed at investigating whether IL-16 genotypes contribute to lung cancer susceptibility.
MATERIALS AND METHODS: IL-16 rs4778889, rs11556218, and rs4072111 genotypic characteristics were determined among 358 lung cancer patients and 716 controls via the polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) methodology.
RESULTS: The highlight finding is that the distributions of genotypic (p=8.6E-10) and allelic (p=0.0001) frequencies of IL-16 rs11556218 was significantly different between cases and controls. In detail, the frequencies of IL-16 rs11556218 heterozygous variant TG and homozygous variant GG were 36.6 and 7.3% among the lung cancer patients, significantly higher than those among the controls (22.5% and 2.6%). On the other way, no difference was observed regarding IL-16 rs4778889 or IL-16 rs4072111.
CONCLUSION: The present study indicates IL-16 rs11556218 G allele is significantly associated with increased Taiwan lung cancer risk. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Genotype; interleukin-16; lung cancer; single nucleotide polymorphism

Mesh:

Substances:

Year:  2020        PMID: 32354900      PMCID: PMC7279827          DOI: 10.21873/invivo.11883

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  48 in total

1.  Lung cancer in never smokers: a new hot area of research.

Authors:  Ramaswamy Govindan
Journal:  Lancet Oncol       Date:  2010-03-19       Impact factor: 41.316

2.  CYP2A6 deletion polymorphism is associated with decreased susceptibility of lung cancer in Asian smokers: a meta-analysis.

Authors:  Yu-liang Liu; Yu Xu; Fan Li; Hong Chen; Shu-liang Guo
Journal:  Tumour Biol       Date:  2013-05-07

3.  Complementary activation of peripheral natural killer cell immunity in nasopharyngeal carcinoma.

Authors:  Ying Zheng; Kai-Yuan Cao; Sze Park Ng; Daniel T T Chua; Jonathan S T Sham; Dora L W Kwong; Mun Hon Ng; Liwei Lu; Bo-Jian Zheng
Journal:  Cancer Sci       Date:  2006-06-29       Impact factor: 6.716

4.  The Association of MMP7 Promoter Polymorphisms With Gastric Cancer.

Authors:  Chun-Kai Fu; Yi-Chun Chien; Hui-Yen Chuang; Yun-Chi Wang; Jeng-Jong Hwang; Mei-Due Yang; Chien-Chih Yu; Jaw-Chyun Chen; Wen-Shin Chang; DA-Tian Bau; Chia-Wen Tsai
Journal:  Anticancer Res       Date:  2020-02       Impact factor: 2.480

5.  The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy.

Authors:  E Kovacs
Journal:  Biomed Pharmacother       Date:  2001-03       Impact factor: 6.529

6.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

7.  Contribution of Matrix Metalloproteinase-2 Promoter Genotypes to Nasopharyngeal Cancer Susceptibility and Metastasis in Taiwan.

Authors:  Shih-Wei Hsu; Chi-Li Gong; Huai-Mei Hsu; Chih-Chang Chao; Yun-Chi Wang; Wen-Shin Chang; Yueh-Ting Tsai; Liang-Chun Shih; Chia-Wen Tsai; DA-Tian Bau
Journal:  Cancer Genomics Proteomics       Date:  2019 Jul-Aug       Impact factor: 4.069

8.  Relationship between CD4(+)/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16.

Authors:  Michiaki Koike; Iwao Sekigawa; Makiko Okada; Michio Matsumoto; Noboru Iida; Hiroshi Hashimoto; Kazuo Oshimi
Journal:  Leuk Res       Date:  2002-08       Impact factor: 3.156

9.  Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.

Authors:  Mun Sem Liew; Joseph Sia; Maud H W Starmans; Ali Tafreshi; Sam Harris; Malcolm Feigen; Shane White; Allan Zimet; Philippe Lambin; Paul C Boutros; Paul Mitchell; Thomas John
Journal:  Cancer Med       Date:  2013-10-16       Impact factor: 4.452

Review 10.  First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.

Authors:  Neha Gupta; Hassan Hatoum; Grace K Dy
Journal:  Int J Nanomedicine       Date:  2013-12-24
View more
  4 in total

1.  The Significant Interaction of Excision Repair Cross-complementing Group 1 Genotypes and Smoking to Lung Cancer Risk.

Authors:  Li-Hsiou Chen; Te-Chun Shen; Chia-Hsiang Li; Kuo-Liang Chiu; Yu-Chen Hsiau; Yun-Chi Wang; Chi-Li Gong; Zhi-Hong Wang; Wen-Shin Chang; Chia-Wen Tsai; Te-Chun Hsia; DA-Tian Bau
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

2.  Significant Association of Chitinase 3-like 1 Genotypes to Asthma Risk in Taiwan.

Authors:  Guan-Liang Chen; Shou-Cheng Wang; Te-Chun Shen; Wen-Shin Chang; Chingju Lin; Te-Chun Hsia; DA-Tian Bau; Chia-Wen Tsai
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

3.  Significant Association of MMP2 Promoter Genotypes to Asthma Susceptibility in Taiwan.

Authors:  Li-Hsiou Chen; Kuo-Liang Chiu; Te-Chun Hsia; Yen-Hsien Lee; Te-Chun Shen; Chia-Hsiang Li; Yi-Cheng Shen; Wen-Shin Chang; Chia-Wen Tsai; DA-Tian Bau
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

4.  Association of functional IL16 polymorphisms with cancer and cardiovascular disease: a meta-analysis.

Authors:  Victor Hugo de Souza; Josiane Bazzo de Alencar; Bruna Tiaki Tiyo; Hugo Vicentin Alves; Evelyn Castillo Lima Vendramini; Ana Maria Sell; Jeane Eliete Laguila Visentainer
Journal:  Oncotarget       Date:  2020-09-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.